Abstract:Recent reports have suggested the involvement of gut microbiota in the progression of colorectal cancer (CRC). We utilized pyrosequencing based analysis of 16S rRNA genes to determine the overall structure of microbiota in patients with colorectal cancer and healthy controls; we investigated microbiota of the intestinal lumen, the cancerous tissue and matched noncancerous normal tissue. Moreover, we investigated the mucosa-adherent microbial composition using rectal swab samples because the structure of the tissue-adherent bacterial community is potentially altered following bowel cleansing. Our findings indicated that the microbial structure of the intestinal lumen and cancerous tissue differed significantly. Phylotypes that enhance energy harvest from diets or perform metabolic exchange with the host were more abundant in the lumen. There were more abundant Firmicutes and less abundant Bacteroidetes and Proteobacteria in lumen. The overall microbial structures of cancerous tissue and noncancerous tissue were similar; howerer the tumor microbiota exhibited lower diversity. The structures of the intestinal lumen microbiota and mucosa-adherent microbiota were different in CRC patients compared to matched microbiota in healthy individuals. Lactobacillales was enriched in cancerous tissue, whereas Faecalibacterium was reduced. In the mucosa-adherent microbiota, Bifidobacterium, Faecalibacterium, and Blautia were reduced in CRC patients, whereas Fusobacterium, Porphyromonas, Peptostreptococcus, and Mogibacterium were enriched. In the lumen, predominant phylotypes related to metabolic disorders or metabolic exchange with the host, Erysipelotrichaceae, Prevotellaceae, and Coriobacteriaceae were increased in cancer patients. Coupled with previous reports, these results suggest that the intestinal microbiota is associated with CRC risk and that intestinal lumen microflora potentially influence CRC risk via cometabolism or metabolic exchange with the host. However, mucosa-associated microbiota potentially affects CRC risk primarily through direct interaction with the host.

Status and prospect of the role of intestinal flora in the development and treatment of gastrointestinal cancer

Advances in the Application of Intestinal Flora in Anti-Tumor Therapy

Gut bacteria and colorectal cancer: from pathogens to therapeutics

Role of gut microbiota in carcinogenesis and treatment for colorectal cancer

The role of intestinal flora in the occurrence and development of colorectal cancer and its mechanism

The Emerging Roles of Human Gut Microbiota in Gastrointestinal Cancer

Correlation of Pathogenesis, Early Diagnosis and Treatment of Colorectal Cancer with Microorganisms

Human Intestinal Lumen and Mucosa-Associated Microbiota in Patients with Colorectal Cancer

The interactions between traditional Chinese medicine and gut microbiota in cancers: Current status and future perspectives

The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer

Emerging roles of the gut microbiota in cancer immunotherapy

The role of the gut microbiota in tumor, immunity, and immunotherapy

The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes

Microbiomics and intestinal tumors

Gut microbes in gastrointestinal cancers

The triangular relationship between traditional Chinese medicines, intestinal flora, and colorectal cancer

Gut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy

Research progress on the correlation between intestinal flora and colorectal cancer

The role of the gut microbiota and probiotics associated with microbial metabolisms in cancer prevention and therapy

Intestinal microbiota: a novel perspective in colorectal cancer biotherapeutics

Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications